Tumor Markers: US, Europe, Japan-Emerging Opportunities and Business Expansion Strategies for Suppliers
News-Press Release
(Newsbox) 18-Jun-2011
Bharatbook.com has this special report, which sources information of cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease.
During the next ten years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.
Geographic Coverage
- France
- Germany
- Italy
- Japan
- Spain
- UK
- USA
Market Segmentation Analysis
- Sales and market shares of major suppliers, by individual tumor marker and country.
- Ten-year test volume and sales forecasts for major tumor markers by country and market segment, including:
- Hospitals
- Commercial/Private Laboratories
- Physician Offices/Group Practices
- Cancer Clinics
- Ambulatory Care Centers
- Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers by country.
- Cancer statistics, etiology and recent developments in the
U.S., Japan and five major European countries.
Current and Emerging Products
- Review of over 200 current and emerging tumor markers, including:
- Biochemical Markers
- Oncogenes
- Growth Factors
- Hormones
- Colony Stimulating Factors
- Lymphokines
- Immunohistochemical Stains, and others.
- Analysis of major immunoassay analyzers used for tumor marker testing, including their operating characteristics,
features and selling prices.
Technology Review
- Assessment of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, artificial intelligence, flow cytometry, biosensors, and their potential applications for tumor marker testing.
- Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.
- Extensive listings of over 500 companies, universities and research centers developing new tumor markers and detection technologies.
Competitive Assessments
- Extensive strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements and new products in R&D.
Worldwide Market Overview
- Estimated universe of laboratories performing tumor marker testing by country.
- Ten-year test volume and sales projections by country.
Business Opportunities and Strategic Recommendations
- Specific new product development opportunities with potentially significant market appeal during the next ten years.
- Design criteria for new products.
- Alternative market penetration strategies.
- Potential market entry barriers and risks.
Methodology
This report is based on interviews with clinical pathologists, laboratory directors, executives from leading diagnostic companies and start-up firms developing innovative products, university scientists, as well as experts from industry associations, venture capital firms and the investment banking community in the U.S., five major European
countries and Japan.
The market projections are also based on questionnaire responses received from hospitals, commercial/private laboratories, physician offices/group practices, cancer clinics and ambulatory care centers in seven countries.
In addition to primary sources of information, a comprehensive review of the most recent technical and business publications, manufacturer product literature, patents, trade association surveys, government studies, marketing and technical meeting presentations, industry analyst reports, and VPG's proprietary data files was conducted.
Table of Contents:
Introduction
Worldwide Market and Technology Overview
A. Cancer Statistics and Etiology
1. Bladder
2. Breast
3. Cervical
4. Colon and Rectum
5. Endometrial
6. Esophagus
7. Head and Neck
8. Leukemia
9. Lung
10. Lymphoma
11. Oral
12. Ovarian
13. Prostate
14. Renal Cell Carcinoma
15. Skin
16. Stomach
17. Uterine
B. Major Current And Emerging Tumor Marker
1. Introduction
2. Tumor Marker Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembrionic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin
16. Lymphocytes CD4/CD8
17. NSE
18. Occult Blood
19. PAP Smear/HPV
20. Prostatic Acid Phosphatase (PAP)
21. Prostate-Specific Antigen (PSA)
22. Squamous Cell Carcinoma Antigen (SCC)
23. TdT
24. Thyroglobulin
25. Tissue Polypeptide Antigen (TPA)
26. Biochemical Tumor Markers
- ADA
- B-Protein
- PNP
- 5'-Nucleotidase
27. Oncogenes
- Abl/abl-bcr
- AIB1
- APC
- BTA 26
- BCL-2
- BCR-ABL
- B-raf
- BRCA
- CD44
- CDK
- C-abl
- C-fos
- C-myb
- C-myc
- CYCD1
- CYP-17
- DPC
- E-myc
- Erb-B
- HER-2/neu
- HPC1
- HSTF
- L-myc
- MET
- MSH
- NEU
- N-myc
- N-telopeptide
- PCA3
- PIK3CA
- PTI-1
- P10
- P40
- P51
• P53
• Ras
• Reg
• RET
• sFas
• Sis
- Src
28. Polypeptide Growth Factors
• Basic Fibroblast Growth Factor
• Beta-TGF
- Cachectin (TNT)
• Calmodulin
• ECFR
• Nerve Growth Factor (NGF)
• Epidermal Growth Factor (EGF)
• Ornithine Decarboxylase
• Transferrin
• Transforming Growth Factor-Alpha
29. Ectopic Hormones
30. Colony Stimulating Factors
31. Lymphokines
• Alpha-Interferon
• B Cell Growth Factors
• B Cell Growth Factor (BCGF)
• Gamma-Interferon
• Interleukin-1 (IL-1)
• Macrophage Activating Factor
32. Immunohistochemical Stains
33. Emerging Tumor Markers
• N-Acetylglucosamine
• Actin
• Alpha-Actin
• Angiogenin
• Angiostatin
• Antineuronal Antibodies
- 7B2
• B72.3
- B-Protein
• Bax
- BCD-F9
• BLCA-4
- Blood Group Antigens A,B,H
• BTA
- CA 50
• CA 72-4/TAG-72
- CA 195
• CA-242
- CA-549
• Cadherin
- CAM 26
For more information kindly visit :
http://www.bharatbook.com/detail.asp?id=200347&rt=Tumor-Markers-US-Europe-Japan-Emerging-Opportunities-and-Business-Expansion-Strategies-for-Suppliers.html
Related Reports
Tumor Markers: US, Europe, Japan-Emerging Opportunities and Business Expansion Strategies for Suppliers
http://www.bharatbook.com/detail.asp?id=200347&rt=Tumor-Markers-US-Europe-Japan-Emerging-Opportunities-and-Business-Expansion-Strategies-for-Suppliers.html
The 2011 CA Tumor Markers: US, Europe, Japan - Test Volume, Sales Forecasts and Supplier Shares by Country
http://www.bharatbook.com/detail.asp?id=155850&rt=The-2011-CA-Tumor-Markers-US-Europe-Japan-Test-Volume-Sales-Forecasts-and-Supplier-Shares-by-Country.html
Or
Contact us at :
Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/BharatBook
Please visit our blog at http://bharatresearch.wordpress.com
Contact Info
Tag Cloud
- Demand Forecast, Europe, Healthcare, Japan, Market, Market Forecast, Market Growth, Market Leaders, Market Report, Market Share, Market Size, Research, USA, Report
Categories
This release was submitted by a Newsbox user. Any communication related to the content of this release should be sent to the release submitter.